Last reviewed · How we verify
Lower dose atropine sulfate eye drops
Low-dose atropine competitively blocks muscarinic acetylcholine receptors in the eye to slow myopia progression.
Low-dose atropine competitively blocks muscarinic acetylcholine receptors in the eye to slow myopia progression. Used for Myopia progression control in children.
At a glance
| Generic name | Lower dose atropine sulfate eye drops |
|---|---|
| Also known as | Lower dose atropine sulfate, Eye drops |
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Muscarinic antagonist / Anticholinergic |
| Target | Muscarinic acetylcholine receptors (M1, M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Atropine is an anticholinergic agent that inhibits accommodation and pupil constriction by antagonizing M1 and M3 muscarinic receptors. At lower doses (typically 0.01%), it retains myopia-slowing efficacy while minimizing pupil dilation and accommodation paralysis side effects associated with conventional higher-dose formulations. The exact mechanism of myopia control remains incompletely understood but involves both accommodation-dependent and accommodation-independent pathways.
Approved indications
- Myopia progression control in children
Common side effects
- Blurred vision
- Photophobia
- Mild pupil dilation
- Ocular irritation
Key clinical trials
- A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops (PHASE3)
- A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: